Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

altRX vs LillyDirect Foundayo

altRX
Graded #92

Higher grade

vs+4.200000000000003
LillyDirect Foundayo
Graded #165

Lower grade

The verdict

altRX takes it — 71.4/100 to 67.2/100.

altRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. altRX is a dual-modality telehealth platform offering compounded GLP-1s plus all four brand-name FDA-approved options — Mounjaro, Ozempic, Wegovy, and Zepbound — the most comprehensive brand-name lineup in…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuealtRX +2
74
72
Dose & formulationaltRX +18
77
59
Clinical oversightaltRX +4
82
78
Labs & monitoringaltRX +1
53
52
FulfillmentLillyDirect Foundayo +7
73
80
Contract termsEven
55
55
altRX · left barLillyDirect Foundayo · right bar

The numbers

MetricaltRXLillyDirect Foundayo
WeighScore71.4/10067.2/100
GradeCC
Scorecard rank#92#165
Semaglutide$149/mo (starting dose, compounded)Not disclosed
Tirzepatide$249/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
altRX

Graded #92 · C

Strengths

  • Offers all four brand-name FDA-approved GLP-1s (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access we've reviewed
  • LegitScript Certified with a publicly verifiable seal
  • Publishes the FDA compounded-medication disclaimer
  • Transparent pricing across all six product tiers (compounded plus four brand-name)
  • All-inclusive pricing — consult, prescription, and shipping with no hidden fees

Where it loses points

  • States-served list not disclosed
  • 503A/503B pharmacy partner not named (only 'multiple USA-certified pharmacies')
  • 503A vs 503B designation not specified
  • No named medical director
  • Corporate physical address not disclosed
LillyDirect Foundayo

Graded #165 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard